Sahasranaman S - Search Results

1

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, Yalamanchili S, Chai A, Sahasranaman S, Punnoose E, Hurst D, Pylypenko H. Kipps TJ, et al. Among authors: sahasranaman s. Leuk Lymphoma. 2015;56(10):2826-33. doi: 10.3109/10428194.2015.1030638. Epub 2015 May 12. Leuk Lymphoma. 2015. PMID: 25797560 Free PMC article. Clinical Trial.

2

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.

Infante JR, Hollebecque A, Postel-Vinay S, Bauer TM, Blackwood EM, Evangelista M, Mahrus S, Peale FV, Lu X, Sahasranaman S, Zhu R, Chen Y, Ding X, Murray ER, Schutzman JL, Lauchle JO, Soria JC, LoRusso PM. Infante JR, et al. Among authors: sahasranaman s. Clin Cancer Res. 2017 May 15;23(10):2423-2432. doi: 10.1158/1078-0432.CCR-16-1782. Epub 2016 Nov 4. Clin Cancer Res. 2017. PMID: 27815358 Clinical Trial.

3

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment.

Ou YC, Preston RA, Marbury TC, Tang Z, Novotny W, Tawashi M, Li TK, Sahasranaman S. Ou YC, et al. Among authors: sahasranaman s. Leuk Lymphoma. 2020 Jun;61(6):1355-1363. doi: 10.1080/10428194.2020.1719097. Epub 2020 Feb 7. Leuk Lymphoma. 2020. PMID: 32031037 Clinical Trial.

4

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.

Ou YC, Tang Z, Novotny W, Cohen A, Wang K, Liu L, Gao Y, Sahasranaman S. Ou YC, et al. Among authors: sahasranaman s. Leuk Lymphoma. 2021 Nov;62(11):2612-2624. doi: 10.1080/10428194.2021.1929961. Epub 2021 Jun 23. Leuk Lymphoma. 2021. PMID: 34159878 Clinical Trial.

5

A supported liquid extraction LC-MS/MS method for determination of concentrations of GDC-0425, a small molecule Checkpoint kinase 1 inhibitor, in human plasma.

Ding X, Chen Y, Sahasranaman S, Shi Y, McKnight J, Dean B. Ding X, et al. Among authors: sahasranaman s. Biomed Chromatogr. 2016 Dec;30(12):1984-1991. doi: 10.1002/bmc.3775. Epub 2016 Jul 5. Biomed Chromatogr. 2016. PMID: 27245274

6

Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.

Chen Y, Zhu R, Ma F, Mao J, Chen EC, Choo EF, Sahasranaman S, Liu L. Chen Y, et al. Among authors: sahasranaman s. Biopharm Drug Dispos. 2018 Nov;39(9):420-430. doi: 10.1002/bdd.2159. Epub 2018 Nov 20. Biopharm Drug Dispos. 2018. PMID: 30335192

7

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.

Mu S, Tang Z, Novotny W, Tawashi M, Li TK, Ou Y, Sahasranaman S. Mu S, et al. Among authors: sahasranaman s. Cancer Chemother Pharmacol. 2020 Feb;85(2):391-399. doi: 10.1007/s00280-019-04015-w. Epub 2019 Dec 26. Cancer Chemother Pharmacol. 2020. PMID: 31875923 Free PMC article.

8

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.

Ou YC, Liu L, Tariq B, Wang K, Jindal A, Tang Z, Gao Y, Sahasranaman S. Ou YC, et al. Among authors: sahasranaman s. Clin Transl Sci. 2021 Mar;14(2):764-772. doi: 10.1111/cts.12948. Epub 2021 Jan 25. Clin Transl Sci. 2021. PMID: 33306268 Free PMC article.

9

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.

Ou YC, Tang Z, Novotny W, Tawashi M, Li TK, Coleman HA, Sahasranaman S. Ou YC, et al. Among authors: sahasranaman s. Br J Clin Pharmacol. 2021 Jul;87(7):2926-2936. doi: 10.1111/bcp.14707. Epub 2021 Jan 14. Br J Clin Pharmacol. 2021. PMID: 33336408 Free PMC article.

10

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.

Zhang H, Ou YC, Su D, Wang F, Wang L, Sahasranaman S, Tang Z. Zhang H, et al. Among authors: sahasranaman s. Pharmacol Res Perspect. 2021 Dec;9(6):e00870. doi: 10.1002/prp2.870. Pharmacol Res Perspect. 2021. PMID: 34664792 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters